Novel Biomarkers in MASLD/MASH
Nov
12
2023
Ballroom A
-
Hynes Convention Center
8:30
- 10:00 AM EST
Description
Abstracts
- IMPACT OF BMI ON NIS2+TM AND ESTABLISHED NON-INVASIVE TESTS FOR THE EVALUATION OF NON-ALCOHOLIC LIVER DISEASE
- DEVELOPMENT OF A NON-INVASIVE CLASSIFIER (FAST-3) TO PREDICT ADVANCED FIBROSIS IN MASH IN LIEU OF LIVER BIOPSIES IN U.S. ADULTS WITH MASLD
- DEVELOPMENT AND VALIDATION OF THE NAFLD FAMILIAL RISK SCORE TO DETECT ADVANCED FIBROSIS: A PROSPECTIVE, MULTICENTER STUDY
- CLINICAL, BIOLOGICAL AND IMAGING PREDICTORS OF AT-RISK METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): COMBINED DATA FROM MULTIPLE THERAPEUTIC TRIALS INCLUDING MORE THAN 6,000 PATIENTS (IN COLLABORATION WITH NAIL-NIT CONSORTIUM)
- THE IMPACT OF GENETIC RISK ON THE PREVALENCE OF ADVANCED FIBROSIS AND CIRRHOSIS IN PROSPECTIVELY ASSESSED PATIENTS WITH TYPE 2 DIABETES
- ABILITY OF SECOND HARMONIC GENERATION/TWO-PHOTON EXCITATION FLUORESCENCE IMAGING AND AI ANALYSIS TO DETECT AND QUANTIFY DRUG-INDUCED, PARAMETER-LEVEL CHANGES OF FIBROSIS: RESULTS FROM THE FALCON-1 CLINICAL TRIAL